<DOC>
	<DOCNO>NCT00540436</DOCNO>
	<brief_summary>The primary objective study evaluate effect GSK1325760A improvement exercise capacity subject pulmonary arterial hypertension ( PAH ) . The secondary objective study evaluate administration GSK1325760A : - The safety tolerability - Improvement PAH - The steady-state plasma pharmacokinetics GSK1325760A</brief_summary>
	<brief_title>Evaluate Efficacy , Safety Pharmacokinetics GSK1325760A Treatment Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<criteria>Inclusion criterion : Subjects must diagnosis Pulmonary Arterial Hypertension ( PAH ) clinical classification Pulmonary Hypertension Group1 The mean right heart catheterization parameter measure 6 month prior administration investigational drug must meet criterion : Mean pulmonary arterial pressure ( mPAP ) &gt; 25 mmHg Pulmonary vascular resistance ( PVR ) &gt; 3 mmHg/L/min Mean pulmonary capillary wedge pressure leave ventricular end diastolic pressure &lt; 15 mmHg ( measurable ) The measure six minute walk distance ( 6MWD ) screen visit range = &gt; 150m &lt; =450m</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Ambrisentan</keyword>
	<keyword>Pulmonary Arterial Hypertension</keyword>
	<keyword>6MWD</keyword>
</DOC>